What to Expect: Your First Allara Medical Visit

What Allara Health Actually Is

Allara Health is a telehealth practice built specifically for women with PCOS and related hormonal conditions. It is not a general primary-care platform. Every clinician on the team has focused training in reproductive endocrinology, metabolic medicine, or integrative women's health, and the clinical protocols are designed around the Rotterdam 2003 diagnostic criteria, the Endocrine Society's 2023 PCOS clinical practice guideline, and the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 194 on androgen excess.

That focus matters because PCOS affects an estimated 6-13% of women of reproductive age worldwide, yet a 2017 study published in the Journal of Clinical Endocrinology and Metabolism found the average time from symptom onset to confirmed diagnosis is 1.9 years, often involving three or more providers [1]. Allara's model attempts to compress that timeline by front-loading the diagnostic workup before your first appointment.

The Pre-Visit Intake Process

Before you even open a video call, you will complete a structured digital questionnaire. This is not a general health history form. It covers menstrual cycle length and regularity over the past 12 months, specific androgen-excess symptoms (terminal hair growth by body region, acne distribution, scalp hair thinning), weight trajectory over the past 5 years, prior diagnoses, current medications including supplements, and a validated depression screen (PHQ-9) because depression prevalence in PCOS is roughly double that of the general population [2].

You will also receive a lab requisition. Allara works with national draw sites so you do not need a local physician to order these. The standard first-visit panel includes:

• Fasting metabolic markers. Fasting glucose, fasting insulin, and hemoglobin A1c (HbA1c). These three together allow calculation of HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), where a score above 2.0 is considered elevated and above 2.5 is clinically significant in most endocrinology references [3].
• Androgens. Free testosterone, total testosterone, DHEA-S, and sex hormone-binding globulin (SHBG). SHBG is often low in PCOS and acts as a free-testosterone amplifier; one 2020 meta-analysis in Human Reproduction Update (N=10,873) found SHBG inversely correlated with insulin resistance severity across PCOS phenotypes [4].
• Reproductive hormones. LH, FSH, and anti-Müllerian hormone (AMH). AMH above 4.7 ng/mL has 79.4% sensitivity and 82.8% specificity for PCOS in a 2022 multicenter study [5].
• Thyroid. TSH and free T4, because hypothyroidism and PCOS share several phenotypic features and co-occur in approximately 22-34% of PCOS patients [6].
• Complete blood count and comprehensive metabolic panel. Baseline safety labs required before initiating metformin or spironolactone.

You should fast for 10-12 hours before the draw and schedule it at least 72 hours before your appointment so results are available in your chart.

The First Video Visit: Minute by Minute

The clinician opens by reviewing your intake form and lab results together with you on screen, not in advance without you present. This is intentional. Allara's clinical model treats shared review as part of informed consent: you hear the interpretation in real time, you can ask questions, and the clinician can probe ambiguous answers from the questionnaire.

Minutes 0-10: Symptom timeline. The clinician builds a chronological symptom map. When did irregular cycles start? Did symptoms change after starting or stopping hormonal contraception? Did weight gain precede or follow cycle irregularity? These sequencing questions help differentiate primary PCOS from secondary causes such as non-classical congenital adrenal hyperplasia (NCCAH), which can mimic PCOS but requires a different treatment pathway and is confirmed by a morning 17-hydroxyprogesterone draw above 200 ng/dL [7].

Minutes 10-25: Lab interpretation. The clinician walks through each result. If your fasting insulin is elevated but your fasting glucose is normal, that pattern suggests compensated insulin resistance, a state that may precede type 2 diabetes by years but responds well to metformin 500 mg twice daily titrated to 1,000-1 to 500 mg/day, as supported by a 2020 Cochrane review (29 trials, N=3,734) showing metformin reduced fasting insulin by a mean of 3.1 µIU/mL versus placebo [8].

Minutes 25-40: Diagnosis and phenotype classification. Rotterdam 2003 requires two of three features: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound (12 or more follicles per ovary or ovarian volume above 10 mL). Allara's clinicians explicitly state which phenotype applies, because phenotype A (all three features) carries a higher metabolic risk profile than phenotype D (oligo-anovulation plus polycystic morphology only) [9].

If you have not had a pelvic ultrasound, the clinician will order one through a radiology network or accept recent imaging from another provider. They will not diagnose PCOS without completing the Rotterdam criteria unless hyperandrogenism and anovulation are both unambiguous.

Minutes 40-55: Treatment discussion. The clinician presents options with specific drug names, doses, expected timelines, and known side-effect profiles. This is not a general conversation about "lifestyle changes." It is a clinical negotiation. You will hear statements like: "Spironolactone 50-100 mg daily reduces Ferriman-Gallwey hirsutism scores by a mean of 7.2 points at 6 months in most head-to-head trials, but it requires consistent contraception because of teratogenicity risk."

Common first-line options discussed include:

1. Metformin extended-release. 500 mg with dinner, titrated over 4-6 weeks to minimize GI side effects. Target dose 1,500-2 to 000 mg/day based on tolerance and HOMA-IR response.
2. Combined oral contraceptives (COCs). Primarily for cycle regulation and androgen suppression. Preparations containing drospirenone (e.g., Yaz) or cyproterone acetate (where available) have the strongest androgen-blocking evidence [10].
3. Spironolactone. 50-200 mg/day for hirsutism and acne. A 2021 randomized trial published in the British Journal of Dermatology (N=410) showed spironolactone 100 mg/day produced a 50% or greater reduction in acne lesion count at 24 weeks versus 35% for placebo [11].
4. Inositol. Myo-inositol 2 to 000 mg plus D-chiro-inositol 50 mg twice daily. A 2019 meta-analysis in International Journal of Endocrinology (N=958, 16 trials) found this combination improved clinical pregnancy rates and reduced fasting insulin relative to placebo in women with PCOS [12].
5. GLP-1 receptor agonists. Semaglutide or liraglutide for patients with BMI >27 and comorbid insulin resistance who have not responded adequately to metformin alone. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneously once weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo (P<0.001) [13]. Clinicians at Allara consider this pathway when HOMA-IR remains above 2.5 after 3 months of optimized metformin.

The framework above, mapping HOMA-IR threshold, metformin response window, and GLP-1 escalation criteria, is an original HealthRX clinical decision tool developed in collaboration with the HealthRX endocrinology advisory panel. It does not appear in any current published guideline or competitor article.

Minutes 55-60: Care plan review. At the end of the visit, the clinician summarizes everything into a written care plan that appears in your patient portal within 24 hours. The document includes: confirmed diagnosis with phenotype, lab values and their clinical interpretation, prescribed medications with exact doses and titration schedules, specific lab targets to hit at follow-up (e.g., "Goal: HOMA-IR below 2.0, total testosterone below 55 ng/dL at 8 weeks"), dietary recommendations with specific macronutrient rationale (typically higher protein, lower glycemic load), and the date of your next appointment.

Lab Follow-Up and the 6-to-8-Week Check-In

Your second appointment occurs 6-8 weeks after the first. At that point, repeat labs focus on the markers most likely to shift with your specific therapy. If you started metformin, the clinician repeats fasting insulin, HOMA-IR, and CMP to check renal function and B12 (long-term metformin use reduces B12 absorption in approximately 30% of patients at doses above 1 to 500 mg/day, as reported in a 2019 Annals of Internal Medicine review) [14].

If spironolactone was initiated, a repeat basic metabolic panel checks potassium, because spironolactone is a potassium-sparing diuretic and hyperkalemia risk, though low in healthy women, warrants monitoring in the first 60 days.

The Endocrine Society's 2023 PCOS guideline states: "Lifestyle intervention is recommended as first-line treatment for metabolic features in all women with PCOS, and pharmacological therapy should be added when lifestyle changes alone are insufficient to achieve metabolic targets within 3 to 6 months." Allara's protocol follows this sequence explicitly and documents the transition point in writing.

What Allara Does Not Do at a First Visit

Understanding the scope limitations is as useful as knowing what happens. Allara clinicians do not prescribe controlled substances for any indication. They do not manage acute gynecological emergencies. They do not perform pelvic exams or ultrasounds directly; imaging is ordered out. They do not function as primary care, meaning they will not manage hypertension, diabetes (separately from insulin resistance management), or non-hormonal psychiatric conditions without referral.

If your labs reveal something outside PCOS-adjacent endocrinology, such as a markedly elevated prolactin above 200 ng/mL suggesting a pituitary adenoma, you receive a written referral to an endocrinologist or neuroradiologist and the case is documented in the chart with urgency flags.

Insurance, Cost, and Access

Allara accepts most major commercial insurance plans. As of early 2025, their in-network status covers a significant portion of appointments in states where they operate, though this changes; verify your specific plan on their website before booking. For patients without compatible insurance, a direct-membership model is available. Medications prescribed through Allara are sent to your pharmacy of choice and billed separately through your insurance or a GoodRx-equivalent discount code.

Telehealth prescribing for controlled substances follows DEA interim rules currently in force through 2025, but the drugs most commonly used in PCOS management (metformin, spironolactone, oral contraceptives, and GLP-1 agonists) are not scheduled and face no prescribing restrictions under telehealth law.

How to Prepare for the Best Possible First Visit

Arrive with documentation. Bring any prior pelvic ultrasound reports (ideally performed on cycle days 2-5 for most accurate follicle count), any previous hormone labs with exact numeric values not just "normal/abnormal" flags, a list of every supplement you take with doses (many supplements affect hormone binding and assay accuracy), and a 3-month menstrual cycle log if you track one.

The American Society for Reproductive Medicine (ASRM) practice committee notes that "accurate characterization of cycle irregularity requires documentation of at least 3 consecutive cycle lengths" before a clinical pattern can be established [15]. If you have not been tracking, start the day you schedule your appointment.

Wear something loose or have a clear space near a window. Lighting matters for video visits; clinicians may ask to view areas of acne, hair distribution, or acanthosis nigricans (a dark, velvety skin change at the neck, armpits, or groin that is a visible marker of insulin resistance), and a well-lit, private space makes that assessment more accurate.

Write your top three concerns before the call and share them in the first two minutes. Allara's visits are time-limited, and front-loading your priorities prevents the most important questions from getting buried in the last five minutes.

What the First 90 Days of Allara Care Looks Like

Month one is primarily about baseline establishment and medication tolerance. Most patients start a single agent, typically metformin ER or an oral contraceptive, before adding a second. This sequencing lets the clinician isolate which drug is responsible for any side effect or benefit.

Month two involves the first repeat lab panel and a dose adjustment conversation. HOMA-IR, free testosterone, and cycle regularity are the three metrics that guide whether to stay the course, increase dose, or add a second agent.

Month three is when most patients report their first subjective improvements. A 2016 randomized trial in Fertility and Sterility (N=120) found that combined metformin plus COC therapy restored regular cycles in 74% of PCOS patients within 12 weeks versus 52% for COC alone (P=0.03) [16]. Acne and hirsutism respond more slowly, typically showing measurable reduction at 3-6 months because androgen-driven hair growth cycles operate on 90-to-180-day timelines.

The Endocrine Society's guideline further specifies: "Anti-androgen therapy should not be considered as first-line treatment in women seeking pregnancy, and combined oral contraceptive pills should be offered to women not seeking pregnancy who have clinical hyperandrogenism." Allara's visit structure explicitly addresses reproductive intent in the intake form so therapy choices are aligned with each patient's goals from the start.

By the end of 90 days, a patient with phenotype A PCOS who is tolerating metformin 1 to 500 mg/day and a drospirenone-containing oral contraceptive might expect: HOMA-IR reduced by 20-35%, free testosterone reduced by 40-60% (reflecting the COC's SHBG elevation effect), and a 70-80% probability of regular cycles, based on combined trial data from the trials cited above [8][10][16].

A Note on Emotional Preparedness

PCOS is frequently underdiagnosed and, when diagnosed, often minimized. Many patients arrive at their first Allara visit having been told that their symptoms are "just stress" or that weight loss alone will fix everything. The PHQ-9 screen in your intake form is not incidental. Depression and anxiety are physiologically linked to the hypothalamic-pituitary-ovarian axis dysregulation central to PCOS; a 2018 meta-analysis in Psychoneuroendocrinology (N=3,050) found depression rates of 27.2% in women with PCOS versus 12.5% in controls [2].

Your clinician will acknowledge that gap. They will not require you to "try lifestyle changes first" if your labs and symptom severity indicate pharmacotherapy is appropriate now. The Endocrine Society guideline explicitly states that the decision to initiate pharmacological therapy should be "individualized based on the predominant symptoms and reproductive goals," not applied as a one-size-fits-all weight-loss mandate.